Research Progress on CRISPR Technology in Biology and Medical Science

doi:10.13560/j.cnki.biotech.bull.1985.2019-0147

Abstract

Abstract: As an emerging technology,CRISPR has been developing rapidly in recent years,and there are great research achievements in disease detection,as well as in the construction of model organisms and gene therapy field. As its simple principle,easy to operate and it can be combined with a variety of technologies,CRISPR technology has great potential in medicine,agriculture,environment and other fields. In addition to the classic CRISPR/cas9 system,scientists have discovered various other types CRISPR/Cas system. Meanwhile,the single base editor（BE）based on Cas9 protein and the CRISPR/Cas13a system that can edit RNA also greatly expand the application range of CRISPR. This article will review the latest development of CRISPR technology and its application in biology,medicine and other fields.

Key words: CRISPR/Cas9, single base editor, RNA editing, gene therapy

YANG Yue, GAO Jun-ru, YANG Liu. Research Progress on CRISPR Technology in Biology and Medical Science[J]. Biotechnology Bulletin, 2020, 36(3): 38-44.

References

[1] Ran FA, Hsu PD, Wright J, et al.Genome engineering using the CRISPR-Cas9 system[J]. Nature Protocols, 2013, 8(11):2281-2308.
[2] Knott GJ, Doudna JA.CRISPR-Cas guides the future of genetic engineering[J]. Science, 2018, 361(6405):866.
[3] Kieper SN, Almendros C, Behler J, et al.Cas4 facilitates PAM-compatible spacer selection during CRISPR adaptation[J]. Cell Reports, 2018, 22(13):3377-3384.
[4] Hsu PD, Scott DA, Weinstein JA, et al.DNA targeting specificity of RNA-guided Cas9 nucleases[J]. Nat Biotechnol, 2013, 31(9):827-832.
[5] Jinek M, East A, Cheng A, et al.RNA-programmed genome editing in human cells[J]. eLife, 2013, 2:e00471.
[6] Hu JH, Miller SM, Geurts MH, et al.Evolved Cas9 variants with broad PAM compatibility and high DNA specificity[J]. Nature, 2018, 556(7699):57-63.
[7] Teng F, Cui T, Feng G, et al.Repurposing CRISPR-Cas12b for mammalian genome engineering[J]. Cell Discovery, 2018, 4:63.
[8] Harrington LB, Burstein D, Chen JS, et al.Programmed DNA destruction by miniature CRISPR-Cas14 enzymes[J]. Science, 2018, 362(6416):839.
[9] Liu JJ, Orlova N, Oakes BL, et al.CasX enzymes comprise a distinct family of RNA-guided genome editors[J]. Nature, 2019, 556:218-223.
[10] Komor AC, Kim YB, Packer MS, et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage[J]. Nature, 2016, 533(7603):420-424.
[11] Kim YB, Komor AC, Levy JM, et al.Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions[J]. Nat Biotechnol, 2017, 35(4):371-376.
[12] Komor AC, Zhao KT, Packer MS, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity[J]. Science Advances, 2017, 3(8):eaao4774.
[13] Li X, Wang Y, Liu Y, et al.Base editing with a Cpf1-cytidine deaminase fusion[J]. Nat Biotechnol, 2018, 36:324.
[14] Gaudelli NM, Komor AC, Rees HA, et al.Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage[J]. Nature, 2017, 551(7681):464-471.
[15] East-Seletsky A, O’connell MR, Knight SC, et al.Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection[J]. Nature, 2016, 538(7624):270-273.
[16] Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al.RNA targeting with CRISPR-Cas13[J]. Nature, 2017, 550(7675):280-284.
[17] Konermann S, Lotfy P, Brideau NJ, et al.Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors[J]. Cell, 2018, 173(3):665-676.
[18] Scotti MM, Swanson MS.RNA mis-splicing in disease[J]. Nature Reviews Genetics, 2016, 17(1):19-32.
[19] 王影, 李相敢, 邱丽娟. CRISPR/Cas9基因组定点编辑中脱靶现象的研究进展[J]. 植物学报, 2018, (4):528-541.
[20] Ihry RJ, Worringer KA, Salick MR, et al.p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells[J]. Nature Medicine, 2018, 24(7):939-946.
[21] Haapaniemi E, Botla S, Persson J, et al.CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response[J]. Nature Medicine, 2018, 24(7):927-930.
[22] Cullot G, Boutin J, Toutain J, et al.CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations[J]. Nature Communications, 2019, 10(1):1136-1136.
[23] Kosicki M, Tomberg K, Bradley A.Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements[J]. Nat Biotechnol, 2018, 36:765.
[24] Kim D, Bae S, Park J, et al.Digenome-seq:genome-wide profiling of CRISPR-Cas9 off-target effects in human cells[J]. Nature Methods, 2015, 12:237-243.
[25] Jin S, Zong Y, Gao Q, et al.Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice[J]. Science, 2019, 364(6437):292-295.
[26] Rossidis AC, Stratigis JD, Chadwick AC, et al.In utero CRISPR-mediated therapeutic editing of metabolic genes[J]. Nature Medicine, 2018, 24(10):1513-1518.
[27] Villiger L, Grisch-Chan HM, Lindsay H, et al.Treatment of a metabolic liver disease by in vivo genome base editing in adult mice[J]. Nature Medicine, 2018, 24(10):1519-1525.
[28] Zuo E, Sun Y, Wei W, et al.Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos[J]. Science, 2019:eaav9973.
[29] Liang P, Xie X, Zhi S, et al.Genome-wide profiling of adenine base editor specificity by EndoV-seq[J]. Nature Communications, 2019, 10(1):67-67.
[30] Kim D, Kim DE, Lee G, et al.Genome-wide target specificity of CRISPR RNA-guided adenine base editors[J]. Nat Biotechnol, 2019.
[31] Kim K, Ryu SM, Kim ST, et al.Highly efficient RNA-guided base editing in mouse embryos[J]. Nat Biotechnol, 2017, 35:435.
[32] Yan S, Tu Z, Liu Z, et al. A huntingtin knockin pig model recapitu-lates features of selective neurodegeneration in huntington’s dise-ase[J]. Cell, 2018, 173(4):989-1002. e13.
[33] Yang W, Liu Y, Tu Z, et al.CRISPR/Cas9-mediated PINK1 dele-tion leads to neurodegeneration in rhesus monkeys[J]. Cell Research, 2019, 29(4):334-336.
[34] Sheth RU, Yim SS, Wu FL, et al.Multiplex recording of cellular events over time on CRISPR biological tape[J]. Science, 2017, 358(6369):1457-1461.
[35] Tang W, Liu DR. Rewritable multi-event analog recording in bacterial and mammalian cells[J]. Science, 2018, 360(6385):eaap8992.
[36] Spanjaard B, Hu B, Mitic N, et al.Simultaneous lineage tracing and cell-type identification using CRISPR-Cas9-induced genetic scars[J]. Nat Biotechnol, 2018, 36(5):469-473.
[37] Mikheikin A, Olsen A, Leslie K, et al.DNA nanomapping using CRISPR-Cas9 as a programmable nanoparticle[J]. Nature Communications, 2017, 8(1):1665.
[38] Rogers ZN, Mcfarland CD, Winters IP, et al.Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice[J]. Nature Genetics, 2018, 50(4):483-486.
[39] Eyquem J, Mansilla-Soto J, Giavridis T, et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection[J]. Nature, 2017, 543(7643):113-117.
[40] Beyret E, Liao HK, Yamamoto M, et al.Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome[J]. Nature Medicine, 2019, 25(3):419-422.
[41] Nelson CE, Wu Y, Gemberling MP, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy[J]. Nature Medicine, 2019, 25(3)427-432.
[42] Yin L, Hu S, Mei S, et al.CRISPR/Cas9 inhibits multiple steps of HIV-1 infection[J]. Hum Gene Ther, 2018, 29(11):1264-1276.